About: An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design
Creator	Brazil, Cunha-Neto, Cv, Herst Ds, Rosa Paulo, São Pe, Harris Wch, Chao
source	BioRxiv; MedRxiv
abstract	The 2013-2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucleocapsid protein (NP). It has been suggested that epitopes on the EBOV NP could form an important part of an effective T-cell vaccine for Ebola Zaire. We show that a 9-amino-acid peptide NP44-52 (YQVNNLEEI) located in a conserved region of EBOV NP provides protection against morbidity and mortality after mouse adapted EBOV challenge. A single vaccination in a C57BL/6 mouse using an adjuvanted microsphere peptide vaccine formulation containing NP44-52 is enough to confer immunity in mice. Our work suggests that a peptide vaccine based on CD8+ T-cell immunity in EBOV survivors is conceptually sound and feasible. Nucleocapsid proteins within SARS-CoV-2 contain multiple class I epitopes with predicted HLA restrictions consistent with broad population coverage. A similar approach to a CTL vaccine design may be possible for that virus.
has issue date	2020-04-06(xsd:dateTime)
bibo:doi	10.1101/2020.02.25.963546
has license	biorxiv
sha1sum (hex)	a2a6e262098539eb875a26800d9f6d3d0d5d1875
schema:url	https://doi.org/10.1101/2020.02.25.963546
resource representing a document's title	An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design
schema:publication	bioRxiv
resource representing a document's body	covid:a2a6e262098539eb875a26800d9f6d3d0d5d1875#body_text
is schema:about of	named entity 'outbreak' named entity 'nucleocapsid' named entity 'Vaccine' named entity 'Design' named entity 'EBOV' named entity 'SURVIVORS' named entity 'RESPONSE TO' covid:arg/a2a6e262098539eb875a26800d9f6d3d0d5d1875 named entity 'specific' named entity 'subjects' named entity 'individuals' named entity 'Protein' named entity 'COVID-19' named entity 'Targeting' named entity '2013-2016' named entity 'T-cell immunity' named entity 'EBOV' named entity 'epitopes' named entity 'vaccine for Ebola' named entity 'protein' named entity 'nucleocapsid protein' named entity 'COVID-19' named entity 'Peptide Vaccine' named entity 'Nucleocapsid Protein' named entity 'CD8+' named entity 'adjuvanted' named entity 'peptide vaccine' named entity 'vaccine' named entity 'EBOV' named entity 'Serum samples' named entity 'aerosolized' named entity 'T-cell' named entity 'aerosol' named entity 'bioRxiv' named entity 'peptide' named entity 'EBOV' named entity 'blood samples' named entity 'bioRxiv' named entity 'T-cell' named entity 'epitopes' named entity 'IL-6' named entity 'EBOV' named entity 'EBOV' named entity 'TLR-4' named entity 'mice' named entity 'epitope' named entity 'microsphere' named entity 'peptides' named entity 'vaccine' named entity 'statistically significant' named entity 'EBOV' named entity 'cytokines' named entity 'EBOV' named entity 'peptide sequences' named entity 'mice' named entity 'bioRxiv' named entity 'human immunodeficiency virus' named entity 'mice' named entity 'vaccine' named entity 'EBOV' named entity 'antibody' named entity 'in-vivo' named entity 'mice' named entity 'C57BL/6' named entity 'aerosol' named entity 'vaccine' named entity 'PBMCs' named entity 'microsphere' named entity 'mice' named entity 'peptide' named entity 'PLGA' named entity 'bioRxiv' named entity 'serum' named entity 'mice' named entity 'mice' named entity 'peptide' named entity 'vaccine' named entity 'peptides'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software